Evidence map›Paper›PMID 34582102›Full record

ArticleClinical and translational allergy2021

Recent advances and developments in COVID-19 in the context of allergic diseases.

Mei Ding, Xiang Dong, Yuan-Li Sun, Milena Sokolowska, Mübeccel Akdis, Willem van de Veen, Ahmet Kursat Azkur, Dilek Azkur, Cezmi A Akdis, Ya-Dong Gao

Open access · goldAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational allergy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. TClinical and translational medicine · 2022
    Trial
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 3 countries.

Mei DingDepartment of Allergology, Zhongnan Hospital of Wuhan University, Wuhan, China.ORCID https://orcid.org/0000-0001-7647-5166
Xiang DongDepartment of Allergology, Zhongnan Hospital of Wuhan University, Wuhan, China.ORCID https://orcid.org/0000-0002-5241-4307
Yuan-Li SunDepartment of Allergology, Zhongnan Hospital of Wuhan University, Wuhan, China.
Milena SokolowskaSwiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.ORCID https://orcid.org/0000-0001-9710-6685
Mübeccel AkdisSwiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.ORCID https://orcid.org/0000-0003-0554-9943
Willem van de VeenSwiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.ORCID https://orcid.org/0000-0001-9951-6688
Ahmet Kursat AzkurDepartment of Virology, Faculty of Veterinary Medicine, University of Kirikkale, Kirikkale, Turkey.ORCID https://orcid.org/0000-0002-5597-8917
Dilek AzkurDivision of Pediatric Allergy and Immunology, Department of Pediatrics, Faculty of Medicine, University of Kirikkale, Kirikkale, Turkey.ORCID https://orcid.org/0000-0002-4396-9087
Cezmi A AkdisSwiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.ORCID https://orcid.org/0000-0001-8020-019X
Ya-Dong GaoDepartment of Allergology, Zhongnan Hospital of Wuhan University, Wuhan, China.ORCID https://orcid.org/0000-0003-1251-7608
University of Zurich · CHWuhan University · CNKırıkkale University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSince the first reports of coronavirus disease 2019 (COVID-19) in Wuhan, China, in December 2019, there have been 198 million confirmed cases worldwide as of August 2021. The scientific community has joined efforts to gain knowledge of the newly emerged virus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the immunopathological mechanisms leading to COVID-19, and its significance for patients with allergies and asthma.

methodsBased on the current literature, recent advances and developments in COVID-19 in the context of allergic diseases were reviewed. RESULTS AND

conclusionsIn this review, we discuss the prevalence of COVID-19 in subjects with asthma, attacks of hereditary angioedema, and other allergic diseases during COVID-19. Underlying mechanisms suggest a protective role of allergy in COVID-19, involving eosinophilia, SARS-CoV-2 receptors expression, interferon responses, and other immunological events, but further studies are needed to fully understand those associations. There has been significant progress in disease evaluation and management of COVID-19, and allergy care should continue during the COVID-19 pandemic. The European Academy of Allergy & Clinical Immunology (EAACI) launched a series of statements and position papers providing recommendations on the organization of the allergy clinic, handling of allergen immunotherapy, asthma, drug hypersensitivity, allergic rhinitis, and other allergic diseases. Treatment of allergies using biologics during the COVID-19 pandemic has also been discussed. Allergic reactions to the COVID-19 vaccines, including severe anaphylaxis, have been reported. Vaccination is a prophylactic strategy that can lead to a significant reduction in the mortality and morbidity associated with SARS-CoV-2 infection, and in this review, we discuss the proposed culprit components causing rare adverse reactions and recommendations to mitigate the risk of anaphylactic events during the administration of the vaccines.

Indexed as

allergyCOVID-19ImpfungmechanismMechanismenSchlüsselwörter: AllergieTherapietreatmentvaccination

Identifiers

PMID34582102
PMCPMC8646609
OpenAlexW3200042704

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.